Key Facts on Outlook: * Overall Sales Growth: Expected in early teens for FY26. * Overall Profit: Anticipated to be maintained for FY26. * Oil Palm Fresh Fruit Bunch (FFB) Arrivals: Projected 15-18% increase for FY26. * Astec LifeSciences EBITDA: Expected to achieve break-even for this financial year. * Astec LifeSciences CDMO Revenue: Aiming over
* Domestic Sales Growth: Reiterated guidance of 30% for FY'26, aiming for >35% growth in remaining quarters. * International Sales Growth: Revised guidance to 5-10% for FY'26 (from 12-15%), expecting recovery in H2. * EBITDA Margin: Maintained at 25-27% for FY'26, with Q1 at 26.3%
* The provided PDF is a notification letter regarding the Q1FY26 earnings call transcript. * It does not contain direct guidance on sales or margin outlook. * The earnings call discussed Q1FY26 results and was held on August 12, 2025. * The official transcript is available via a link provided in the document: https:
* FY26 Domestic Revenue Growth: Reiterated 30% guidance. * FY26 International Revenue Growth: Revised to 5-10% guidance (from 12-15% earlier). * FY26 EBITDA Margin Guidance: Maintained 25-27% (Q1 FY26 achieved 26.3%). * Gross Profit Margin (Q1 FY26): Increased to 68.4%. * FY26 CAPEX: Maintained at over Rs. 250 crores. * Renal Business Market Share
* **FY26 Domestic Revenue Growth Guidance:** Reaffirmed at 30%. * **FY26 International Revenue Growth Guidance:** Revised to 5-10% (previously 12-15%). * **FY26 EBITDA Margin Guidance:** Maintained in the range of 25-27%. * **FY26 CAPEX Guidance:** Over Rs. 250 crores for new facilities. * **R&D Spend:** Expected to rise as a percentage of revenue,
* Domestic Sales Outlook: Reiterate 30% revenue growth for FY26. * International Sales Outlook: Revised to 5-10% revenue growth for FY26 (from earlier 12-15%). * EBITDA Margin Guidance: Maintain in the range of 25% to 27% for FY26. * R&D Spend: Expected to increase as a percentage of revenue, focusing on high-end
* Overall FY26 Top-line Growth: Expected to be in “early teens.” * Overall FY26 Profit: “Same expectation for profit” maintained. * Crop Protection EBIT Margin: Anticipated at 28-30% for FY26. * Astec LifeSciences: Expected to achieve EBITDA break-even in FY26, targeting Rs. 500 crore turnover. * Dairy EBITDA Margin: Projected at 5.5-6% for FY26
Key Facts on Outlook: * Overall FY26 sales growth anticipated in "early teens" (revised from 16-18% previously). * Overall profit expected to be maintained for FY26. * Crop Protection EBIT margin target: 28-30%; top-line growth being re-evaluated due to seasonal challenges. * Astec LifeSciences aims for EBITDA break-even in FY26, targeting over
* Overall Top-Line Growth: Expected in "early teens" for FY26. * Overall Profitability: Management maintains "same expectation" for profit. * Crop Protection (CP) Segment: EBIT margin projected at "close to 28% to 30%". Top-line growth assessment ongoing post-season. * Oil Palm (Vegetable Oil) Segment: Fresh Fruit Bunch (FFB)
* Overall Sales Outlook: Expected to achieve “early teens” top-line growth for Fiscal Year ‘26. * Overall Profitability: Management reiterates its profit expectations for FY ‘26. * Astec LifeSciences: Targeting EBITDA break-even and Rs. 500 crore turnover for FY ‘26, projecting over 30% annual growth beyond FY ‘26. * Crop Protection: Aiming for 28-30%
Key Facts on Outlook: * Astec LifeSciences Sales: Targeting Rs. 500 crores turnover in FY26. * Ashitaka (Maize Herbicide) Sales Potential: Theoretical potential of Rs. 200 crores in 3-4 years, with potential for upward revision due to rising corn acreage. * Vegetable Oil Sales: Expecting 15-18% increase in Fresh Fruit Bunch (FFB) arrivals
* FY26 Revenue Guidance: Rs. 860+ crore. * FY26 PAT Guidance: Rs. 80-110 crore range (tariff dependent). * FY26 End Order Book Target: Rs. 1100 crore. * Long-Term Top Line Growth: Doubling in 4-5 years. * Major US Expansion: Houston plant by 2026. * Strategic Acquisitions: WesTech (India) and UK company. * US Tariff Impact: Mitigated by